Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human ...

The company will engage in BIO One-on-One Partnering™ meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

GSK GSK2.07%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

MIAMI, FL / ACCESS Newswire / May 28, 2025 / MIRA Pharmaceuticals ... taking place in Boston, MA from June 16-19, 2025. The Company has a full schedule of BIO One-on-One Partnering™ meetings ...

GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British pharma giant said Wednesday that it will pay ...

The treatment, made by Boston Pharmaceuticals, is ready to enter the last stage of clinical tests, the UK drugmaker said Wednesday. The medicine could become a blockbuster, according to analysts ...